Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.

The scientific poster, titled “ RNA Sequencing to Help Identify Rare Genetic Disorders, ” explores the diagnostic value of leveraging RNA sequencing data to reclassify variants of uncertain ...

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

Scientists have decoded a century-old killer hiding in a preserved lung. New genetic evidence from 1918 reveals the virus was ...

Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and announces that the U.S. Food and Drug Administration ...

The global Live Cell RNA Detection Market is set for robust expansion, with valuation projected to rise from USD 3.4 billion ...

A new study suggests an enzyme unique to Homo sapiens may have made us more competitive water seekers than our closest ...

Over the last few years, scientists and entrepreneurs have flocked to developing medicines that target RNA, the genetic ...

Studying the process of brain formation illuminates just how much of development is a series of tiny miracles. Only a few ...

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.